This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Casimiro, D. R. Articles by Shiver, J. Search for Related Content PubMed PubMed Citation Articles by Casimiro, D. R. Articles by Shiver, J.

 Previous Article  |  Next Article 

Journal of Virology, October 2004, p. 11434-11438, Vol. 78, No. 20
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.20.11434-11438.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Heterologous Human Immunodeficiency Virus Type 1 Priming-Boosting Immunization Strategies Involving Replication-Defective Adenovirus and Poxvirus Vaccine Vectors

Danilo R. Casimiro,^1* Andrew J. Bett,¹ Tong-ming Fu,¹ Mary-Ellen Davies,¹ Aimin Tang,¹ Keith A. Wilson,¹ Minchun Chen,¹ Romnie Long,¹ Troy McKelvey,¹ Michael Chastain,¹ Sanjay Gurunathan,² Jim Tartaglia,³ Emilio A. Emini,^1, and John Shiver¹

Department of Viral Vaccine Research, Merck Research Laboratories, Merck & Co., West Point,¹ Aventis-Pasteur, Inc., Swiftwater, Pennsylvania,² Aventis-Pasteur, Ltd., Toronto, Ontario, Canada³

Received 16 February 2004/ Accepted 5 June 2004

We compared the human immunodeficiency virus type 1 (HIV-1)-specific cellular immune responses elicited in nonhuman primates by HIV-1 gag-expressing replication-defective adenovirus serotype 5 (Ad5) or poxvirus vectors, used either alone or in combination with each other. The responses arising from a heterologous Ad5 priming-poxvirus boosting regimen were significantly greater than those elicited by homologous regimens with the individual vectors or by a heterologous poxvirus priming-Ad5 boosting regimen. The heterologous Ad5 priming-poxvirus boosting approach may have potential utility in humans as a means of inducing high levels of cellular immunity.

Present address: International AIDS Vaccine Initiative, New York, NY 10038.

This article has been cited by other articles:

• Kaufman, D. R., Goudsmit, J., Holterman, L., Ewald, B. A., Denholtz, M., Devoy, C., Giri, A., Grandpre, L. E., Heraud, J.-M., Franchini, G., Seaman, M. S., Havenga, M. J. E., Barouch, D. H. (2008). Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in Mice. J. Virol. 82: 6829-6837 [Abstract] [Full Text]  
• Walker, B. D., Burton, D. R. (2008). Toward an AIDS Vaccine. Science 320: 760-764 [Abstract] [Full Text]  
• Yang, K., Whalen, B. J., Tirabassi, R. S., Selin, L. K., Levchenko, T. S., Torchilin, V. P., Kislauskis, E. H., Guberski, D. L. (2008). A DNA Vaccine Prime Followed by a Liposome-Encapsulated Protein Boost Confers Enhanced Mucosal Immune Responses and Protection. J. Immunol. 180: 6159-6167 [Abstract] [Full Text]  
• Rodriguez, A., Goudsmit, J., Companjen, A., Mintardjo, R., Gillissen, G., Tax, D., Sijtsma, J., Weverling, G. J., Holterman, L., Lanar, D. E., Havenga, M. J. E., Radosevic, K. (2008). Impact of Recombinant Adenovirus Serotype 35 Priming versus Boosting of a Plasmodium falciparum Protein: Characterization of T- and B-Cell Responses to Liver-Stage Antigen 1. Infect. Immun. 76: 1709-1718 [Abstract] [Full Text]  
• Radosevic, K., Wieland, C. W., Rodriguez, A., Weverling, G. J., Mintardjo, R., Gillissen, G., Vogels, R., Skeiky, Y. A. W., Hone, D. M., Sadoff, J. C., van der Poll, T., Havenga, M., Goudsmit, J. (2007). Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon. Infect. Immun. 75: 4105-4115 [Abstract] [Full Text]  
• Hanke, T., McMichael, A. J., Dorrell, L. (2007). Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88: 1-12 [Abstract] [Full Text]  
• Capone, S., Meola, A., Ercole, B. B., Vitelli, A., Pezzanera, M., Ruggeri, L., Davies, M. E., Tafi, R., Santini, C., Luzzago, A., Fu, T.-M., Bett, A., Colloca, S., Cortese, R., Nicosia, A., Folgori, A. (2006). A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques. J. Virol. 80: 1688-1699 [Abstract] [Full Text]  
• Miyahira, Y., Takashima, Y., Kobayashi, S., Matsumoto, Y., Takeuchi, T., Ohyanagi-Hara, M., Yoshida, A., Ohwada, A., Akiba, H., Yagita, H., Okumura, K., Ogawa, H. (2005). Immune Responses against a Single CD8+-T-Cell Epitope Induced by Virus Vector Vaccination Can Successfully Control Trypanosoma cruzi Infection. Infect. Immun. 73: 7356-7365 [Abstract] [Full Text]  
• Wu, L., Kong, W.-p., Nabel, G. J. (2005). Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens. J. Virol. 79: 8024-8031 [Abstract] [Full Text]